louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04171362: The Effect of Connective Tissue Massage in Patients With Migraine
Official title: The Effect of Connective Tissue Massage in Patients With Migraine
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Migraine With Aura
Migraine
Migraine Without Aura
Connective Tissue Diseases
Lead sponsor: Ankara Yildirim Beyazıt University
Sponsor class: OTHER
First posted: 2019-11-20
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to investigate the effectiveness of connective tissue massage in patients with migraine


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Migraine Disease
* Being volunteer

Exclusion Criteria:

* Serious psychiatric problems with mental and / or communication problems Neurological, inflammatory or endocrine disease

Primary outcomes:
measure: Migraine Disability Assessment Test
timeFrame: change from baseline at 4 weeks
Secondary outcomes:
measure: Pittsburgh Sleep Quality Index
timeFrame: change from baseline at 4 weeks
measure: Hospital Anxiety and Depression Scale (
timeFrame: change from baseline at 4 weeks
measure: Nothingham Health Profile
timeFrame: Before the treatment and end of 4 weeks
measure: Allodynia Symptom Checklist
timeFrame: change from baseline at 4 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Özge Çoban
Study officials:
References:
Clinical trial NCT02238262: Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
Official title: Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-09-12
Enrollment: 2318
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with essential hypertension being treated in hospitals

Brief summary: The aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals


Eligibility criteria: Inclusion Criteria:

* Patients with diagnosis of essential hypertension
* Minimum age of 18 years

Exclusion Criteria:

* NA

Primary outcomes:
measure: Change in clinic blood pressure
timeFrame: up to 14 days
measure: Number of patients with adverse drug reactions
timeFrame: up to 14 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00374062: Effect of the Subconscious on Mohs Micrographic Surgery
Official title: Effect of the Subconscious on Mohs Micrographic Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Basal Cell Carcinoma
Squamous Cell Carcinoma
Keywords: Mohs Surgery
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2006-09-08
Enrollment: 150
Sex: ALL
Minimum age (years): 25
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to determine if relaxation therapy improves patient satisfaction with Mohs micrographic surgery.

Detailed description: Patients are instructed in relaxation techniques. The goal of this study is to determine how relaxation techniques affect the patient's Mohs micrographic surgery experience.

Eligibility criteria: Inclusion Criteria:

* Age 25 and older
* Subjects are undergoing micrographic Mohs surgery for facial basal and squamous cell carcinoma.
* The subjects are in good health.
* The subjects have willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator.

Exclusion Criteria:

* Subjects who have wound healing problems.
* Subjects who have had prior Mohs surgery.
* Subjects who are smokers.
* Subjects who are currently using anticoagulation therapy
* Subjects who have a history of bleeding disorders.
* Subjects who are unable to understand the protocol or to give informed consent
* Subjects with known mental illness or other psychological conditions, such as psychotic disorders, mood disorders, anxiety disorders, cognitive disorders, depression with psychotic features, dissociative disorders.
* Subjects who are taking medications that may affect healing such as prednisone, or any immunosuppressants.
* Subjects who are immunocompromised.
* Subjects who have Diabetes Mellitus or any other condition determined by the PI to affect healing.

Primary outcomes:
measure: Patient anxiety
timeFrame: 1 day
Secondary outcomes:
measure: Scar appearance
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Murad Alam, MD
state: Illinois
Study officials:
affiliation: Northwestern University
name: Murad Alam, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05055362: Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
Official title: Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Kidney Diseases
Overweight and Obesity
Lead sponsor: University of Florida
Sponsor class: OTHER
Collaborators: name: National Kidney Foundation, United States
First posted: 2021-09-24
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this research is to determine the effect a spiced-infused baked good has on inflammatory biomarkers in adults who are overweight and/or who has chronic kidney disease. Participants will be involved for 10 days in this research study.

Detailed description: The dietary intervention will for 10-days, in which participants will eat a baked good each day for a total of 10 days. This baked good contains honey and spices (cinnamon and turmeric). At the first day of the study, participants will provide a urine sample, saliva sample, be weighed, take a pregnancy test, complete a total of 3 surveys - dietary and spice intake and demographics. Each survey will take no more than 10 minutes for a total of 30 minutes. At the end of the 10 days, participants will provide a saliva sample and complete 2 surveys - dietary and spice intake. Each survey will take no more than 10 minutes for a total of 20 minutes. Each day of the baked good intervention, participants will tick off the amount of baked good consumed (100%, 75%, 50%, 25%, 0%).

Eligibility criteria: Inclusion Criteria:

* adults who have been diagnosed with CKD and/or have a BMI \>24.9
* have no additional chronic diseases or GI disorders or GI disturbances
* age 18 years or older
* no food allergies or dietary restrictions
* all with no contraindications to consuming anything by mouth as per their physician

Exclusion Criteria:

* no diagnosis of CKD or BMI \<24.9
* GI disorders, diagnosed with other chronic diseases and conditions, gastrointestinal disturbances
* pregnant and/or lactating
* under 18 years old
* food allergies to wheat, almonds, or aversion to turmeric, cinnamon, and honey. -Dietary restrictions as medically indicated
* trouble chewing/swallowing as confirmed by physician

Primary outcomes:
measure: inflammation markers
timeFrame: 10 days
measure: inflammation markers
timeFrame: 10 days
Secondary outcomes:
measure: Dietary and Spice habits
timeFrame: 10 days
Other outcomes:
measure: Albuminuria
timeFrame: 10 days
Locations:
city: Gainesville
country: United States
facility: University of Florida
state: Florida
Study officials:
affiliation: University of Florida
name: Jeanette Andrade
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01222962: Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers
Official title: Study of the Effect of Food on the Pharmacokinetics of DHA and PQP After Single Oral Administration of Eurartesim™ in Healthy Male Adult Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Malaria, Falciparum
Lead sponsor: sigma-tau i.f.r. S.p.A.
Sponsor class: INDUSTRY
Collaborators: name: CPR Pharma Services Pty Ltd, Australia
First posted: 2010-10-18
Enrollment: 37
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study was designed to assess the effect of food on the extent and rate of absorption of Dihydroartemisinin (DHA) and Piperaquine Phosphate (PQP) administered as a fixed dose combination (Eurartesim™).


Eligibility criteria: Inclusion Criteria:

* Caucasian healthy males aged between 18 and 50 years(inclusive).
* Body Mass Index (BMI) between 19.0 kg/m2 and 27.0 kg/m2 inclusive, with a minimum body weight of 75 kg.
* Agreed to use two approved methods of contraception from Screening and until 90 days after administration of the study drug
* Had given written informed consent to participate in this study in accordance with local regulations.

Exclusion Criteria:

* Had received or was anticipated to receive a prescription medication within 14 days prior to the start of dosing or an over-the-counter medicine 48 hours prior to the start of dosing.
* Abnormal laboratory test results deemed clinically significant by the Medical Officer.
* Positive urine drug test (e.g. opiates and cannabinoids) or alcohol breath test.
* History of significant drug allergies or significant allergic reaction.
* Receipt of blood or blood products, or loss or donation of 450 mL or more of blood within 90 days before the first dose administration.

Primary outcomes:
measure: tmax, Cmax, AUC0-last, AUC0-24 [PQ], and AUC0-inf, λz, t1/2, Cl/F, Vz/F [DHA].
timeFrame: from the day of study drug administration, till Day 7 follow-up
Secondary outcomes:
measure: Number of Treatment Emergent Adverse Events
timeFrame: Day 0 and till Day 30 follow-up
measure: Hematology and blood chemistry changes respect to baseline values
timeFrame: Day 0, day 2, day 30
measure: QTc interval prolongation
timeFrame: Day 0, day 2, day 30
Other outcomes:
Locations:
city: Adelaide
country: Australia
facility: CMAX, a division of IDT Australia Limited
Study officials:
References:
Clinical trial NCT06649162: A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Official title: A Multi-center, Prospective, Cohort Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Type 2 Diabetes
Lead sponsor: Boryung Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-10-18
Enrollment: 10000
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with type 2 diabetes scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone

Brief summary: The purpose of this study is to identify the risk of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes in clinical practice and to evaluate the clinical usefulness of Dapagliflozin/Pioglitazone combination therapy


Eligibility criteria: Inclusion Criteria:

* Among patients with type 2 diabetes, those who are scheduled to administer a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1)
* Those who voluntarily signed a written personal information collection and usage agreement after listening to an explanation about the objective and method, etc. of this clinical study.

Exclusion Criteria:

* Those who have a history of taking a fixed-dose combination of dapagliflozin/pioglitazone at baseline (visit 1).
* Those who are expected to need insulin prescription during the study period.

Primary outcomes:
measure: Percentage of subjects who correspond to high risk score (≥8) by evaluating simple NAFLD score
timeFrame: Baseline (visit 1)
Secondary outcomes:
Other outcomes:
Locations:
city: Andong
country: Korea, Republic of
facility: Andong Hospital
state: Gyeongsangbuk-do
city: Seoul
country: Korea, Republic of
facility: Konkuk University medical center
Study officials:
References:
Clinical trial NCT04041362: the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
Official title: A Phase II, Open-label, Controlled, Proof-of-concept Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: HIV-1 Infection
Keywords: HIV
UB-421
Lead sponsor: United BioPharma
Sponsor class: INDUSTRY
First posted: 2019-08-01
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study assess the safety, tolerability, and efficacy in reducing viral load and proviral DNA of UB-421 administered as an add-on to the ART in ART-experienced viremic HIV-1 subjects.


Eligibility criteria: Inclusion Criteria:

1. HIV-1 seropositive
2. Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg.
3. have been receiving antiretroviral therapy (ART) for more than 2 years

Exclusion Criteria:

1. Any previous exposure to a mAb within 12 weeks prior to the first dose of UB-421 treatment.
2. Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined during the screening period, medical history, and/or physical examination that, in Investigator's opinion, would preclude the subject from participating in this study.
3. History of anaphylaxis to monoclonal antibodies.
4. Any vaccination within 8 weeks prior to the first dose of UB-421.

Primary outcomes:
measure: treatment related TEAEs
timeFrame: 16 Weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06913062: Neural Mobilization in Cervico-Brachial Neuralgia
Official title: Combining Neural Mobilization With Conventional Rehabilitation: A New Approach to Cervico-Brachial Neuralgia Management
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervico Brachialgia
Keywords: cervico-brachial neuralgia
neural mobilization
pain
function
Lead sponsor: Hopital Charles Nicolle
Sponsor class: OTHER
First posted: 2025-04-06
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aimed to compare the effectiveness of neural mobilization (NM) combined with conventional rehabilitation versus conventional rehabilitation alone in patients with chronic common cervico-brachial neuralgia (CBN), focusing on pain, cervical range of motion (ROM), functional disability, and psychological state.

A randomized controlled trial was conducted including patients with chronic CBN. They were randomized into two groups: control group received standard rehabilitation, while NM Group received the same treatment with additional NM techniques. Evaluations were conducted pre- and post-treatment, assessing pain, cervical ROM, functional disability and psychological state via the Beck Depression Inventory.


Eligibility criteria: Inclusion Criteria:

* patients over 18 years old
* with chronic common CBN

Exclusion Criteria:

* secondary CBN
* prior cervical surgery
* cervical trauma
* recent central or peripheral neurological conditions
* unstable cauda equina lesions,
* untreated tumors or infections.

Primary outcomes:
measure: pain intensity
timeFrame: Outcome measures were collected at baseline prior to the intervention (T0) and at the end of the treatment period (T1).
Secondary outcomes:
measure: mobility
timeFrame: Outcome measures were collected at baseline prior to the intervention (T0) and at the end of the treatment period (T1).
measure: function
timeFrame: Outcome measures were collected at baseline prior to the intervention (T0) and at the end of the treatment period (T1).
measure: depression
timeFrame: Outcome measures were collected at baseline prior to the intervention (T0) and at the end of the treatment period (T1).
Other outcomes:
Locations:
city: Tunis
country: Tunisia
facility: Charles Nicolle Hospital
Study officials:
References:
Clinical trial NCT03768362: Comparison of Medial Rectus Resection and Plication in Exotropic Patients
Official title: Comparison of Medial Rectus Resection and Plication in Exotropic Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Exotropia
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2018-12-07
Enrollment: 52
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose: To determine the surgical outcomes of the plication technique in comparison with the resection method on exotropic patients.

Methods: In this randomized clinical trial, a total of 52 exotropic patients (female, 51.9%) who are candidate for medial rectus strengthening will be randomly classified into plication (n=24) and resection (n=28) groups. The comprehensive visual and ocular examinations will be performed on all study subjects and they will be followed- up for three months postoperatively. Plication technique is the same as resection up to muscle suturing, in the next step, the sutures are passed through 2 scleral bites at 1 mm anterior to the muscle insertion, then the muscle was folded toward inside or outside by pulling and joining the sutures.


Eligibility criteria: Inclusion Criteria:

Patients with a residual exotropia and history of uni- or bilateral lateral rectus recession or recession and resection (R \&R) and those exotropic patients who were going to have already recession and resection (R \& R) operation due to unilateral constant exotropia will be considered as eligible cases to be included.

Exclusion Criteria:

Subjects with a history of prematurity, intellectual disability, lack of central fixation (nystagmus, eccentric fixation, retinopathy of prematurity) subjects with systemic or other ocular diseases, neurological disorders, uncooperative patients and participants with less than three-month postoperative follow-up will be excluded from this study.

Primary outcomes:
measure: Postoperative ocular deviation
timeFrame: three months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01460862: Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
Official title: Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Asthma
Keywords: Asthma
Omalizumab
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2011-10-27
Enrollment: 0
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with uncontrolled asthma and using high-dose ICS prior to initiating omalizumab.

Brief summary: A retrospective database analysis to evaluate the impact of omalizumab on the use of corticosteroid, emergency-department visits and hospitalizations among patients with uncontrolled asthma and using high-dose Inhaled Corticosteroids (ICS) prior to initiating omalizumab.


Eligibility criteria: Inclusion Criteria:

* ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis,
* on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline,
* uncontrolled asthma at baseline.

Exclusion Criteria:

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Frequency of emergency-department visits and hospitalizations
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References: